Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis.
Ghadeer K DawwasEric A DietrichDavid E WinchesterAlmut G WintersteinRichard SegalHaesuk ParkPublished in: Pharmacotherapy (2019)
In this population-based cohort of incident ACS patients, ticagrelor was associated with a reduced rate of recurrent nonfatal CVD events, major and minor bleeding events compared with prasugrel.